BUZZ - TriSalus shares surge after FDA approves liver treatment device
路透社2026/09/23 13:53Latest Developments
September 23 - ** Cancer treatment company TriSalus (TLSI.O) shares rose 7.5% to $5.3
** The company (link)'s Trinav Advance device received FDA approval, further expanding its portfolio of liver-targeted therapy products
** The company plans to launch the device on a small scale in the coming weeks
** Five brokers rate the stock as "Buy"; the median price target is $9 — data compiled by LSEG
** Including the day's movement, the stock is down 29.4% so far this year
(To assist non-English speakers, Reuters provides automated translations of its reports into several other languages. As automated translation may contain mistakes or lack required context, Reuters does not guarantee the accuracy of the automated translation and provides it solely for reader convenience. Reuters accepts no responsibility for any damage or loss caused by the use of automated translation services.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Silver Price Forecast: XAG/USD trades flat around $53 ahead of US inflation data
Swiss Franc holds ground as US Dollar consolidates ahead of CPI inflation data
Net profit surges fivefold but masks decline in core business; crypto mining companies' shift to AI poses hidden risks
Marathon Holdings' Q3 net profit reached $632 million, up 413% year-on-year. However, its mining revenue declined by 35%. The company relied on selling 13,500 BTC to pay off debts and is now betting on AI infrastructure, increasing the risk of an imbalanced profit structure.
Lithium-For-Earth Raises KRW 1.32 Billion in Private Placement
Crypto prices
More
